Top 5 Clean Energy Companies To Buy For 2014

According to GuruFocus list of 5-year lows, these Guru stocks have reached their 5-year lows: Rentech Nitrogen Partners LP, Francesca�� Holdings Corp, American Residential Properties Inc, Silver Bay Realty Trust Corp, and Western Asset Mortgage Capital Corp

Rentech Nitrogen Partners LP (NYSE:RNF) Reached the 5-year Low of $16.02

The prices of Rentech Nitrogen Partners LP (NYSE:RNF) shares have declined to close to the 5-year low of $16.02, which is 68.9% off the 5-year high of $49.18. Rentech Nitrogen Partners LP is owned by one guru we are tracking. Among them, none have added to their positions during the past quarter. 1 reduced their positions. Rentech Nitrogen Partners LP is a limited partnership formed by Rentech, a publicly traded provider of clean energy solutions and nitrogen fertilizer, to own, operate and grow nitrogen fertilizer business. Rentech Nitrogen Partners Lp has a market cap of $623.019 million; its shares were traded at around $16.02 with and P/S ratio of 2.02. The dividend yield of Rentech Nitrogen Partners Lp stocks is 7.80%.

10 Best Gas Stocks To Own Right Now: Aegion Corp (AEGN)

Aegion Corporation, incorporated on August 17, 2011, is engaged in infrastructure protection, providing technologies and services to protect against the corrosion of industrial pipelines and for the rehabilitation and strengthening of sewer, water, energy and mining piping systems and buildings, bridges, tunnels and waterfront structures. The Company operates in five segments: Energy and Mining, North American Sewer and Water Rehabilitation, European Sewer and Water Rehabilitation, Asia-Pacific Sewer and Water Rehabilitation and Commercial and Structural. The Company�� business activities include manufacturing, distribution, installation, coating and insulation, cathodic protection, research and development and licensing. Its products and services are utilized and performed in more than 100 countries across six continents. The Company offers solutions for rehabilitating aging or deteriorating infrastructure and protecting new infrastructure from corrosion. In June 2013, Aegion Corporation announced that it has sold its 50% interest in Insituform Rohrsanierungstechniken GmbH (Insituform-Germany) to Per Aarsleff A/S. In July 2013, Aegion Corp announced that it has completed the acquisition of Brinderson, L.P.

In March 2012, the Company organized United Special Technical Services LLC (USTS), a joint venture located in the Sultanate of Oman between United Pipeline Systems and Special Technical Services LLC (STS), for the purpose of executing pipeline, piping and flow line high-density polyethylene lining services throughout the Middle East and Northern Africa. United Pipeline Systems holds a 51% equity interest in USTS and STS holds the remaining 49% equity interest. In November 2012, the Company acquired the shares of its joint venture partner, SPML Infra Limited (SPML), an unaffiliated Indian contractor, in Insituform Pipeline Rehabilitation Private Limited (Insituform-India) in order to continue to pursue business opportunities in India involving CIPP installations and third party tube! sales, as well as to promote its other products and services. In January 2012, the Company purchased Fyfe Group�� Latin American operations (Fyfe LA), which included all of the equity interests of Fyfe Latin America S.A., a Panamanian entity (and its interest in various joint ventures located in Peru, Costa Rica, Chile and Colombia), Fyfe Latin America S.A. de C.V., an El Salvadorian entity, and Fibrwrap Construction Latin America S.A., a Panamanian entity. In April 2012, the Company purchased Fyfe Group�� Asian operations (Fyfe Asia), which included all of the equity interests of Fyfe Asia Pte. Ltd, a Singaporean entity (and its interest in two joint ventures located in Borneo and Indonesia), Fyfe (Hong Kong) Limited, Fibrwrap Construction (M) Sdn Bhd, a Malaysian entity, Fyfe Japan Co. Ltd and Fibrwrap Construction Pte. Ltd and Technologies & Art Pte. Ltd., Singaporean entities.

Energy and Mining

The Company�� energy and mining operations provide rehabilitation and corrosion protection services for industrial, mineral, oil and gas piping systems and structures. The Company also offers products for gas release and leak detection systems. Its worldwide energy and mining operations are headquartered in Chesterfield, Missouri. These operations are conducted through its various subsidiaries (United Pipeline Systems based in Durango, Colorado, Bayou based in New Iberia, Louisiana, Corrpro based in Houston, Texas, CRTS based in Tulsa, Oklahoma and Hockway based in the United Arab Emirates). Certain of its energy and mining operations outside of the United States are conducted through its wholly owned subsidiaries in the United Kingdom, Portugal, Chile, Canada, Argentina, Brazil and the United Arab Emirates and through its joint ventures in Canada, Mexico, Oman, Singapore, Saudi Arabia and Morocco.

United Pipeline Systems performs pipeline rehabilitation services using its Tite Liner process. Its Bayou business performs internal and external pipeline coating, lini! ng, weigh! ting and insulation services, as well as specialty fabrication services for offshore deep water installations, including project management and logistics. Its Corrpro business performs fully-integrated corrosion prevention services including: engineering; product and material sales; construction and installation; inspection, monitoring and maintenance; andcoatings. Its CRTS business specializes in the application of internal and external corrosion coatings services and equipment for new pipeline construction projects. Its Hockway business performs cathodic protection, engineering and design, manufacturing, maintenance and installation services to the oil and gas markets.

Water and Wastewater Rehabilitation Operations

The Company�� sewer rehabilitation activities are conducted principally through installation and other construction operations performed directly by its subsidiaries. In certain geographic regions, the Company has granted licenses to unaffiliated companies. Its North American Water and Wastewater operations, including research and development, engineering, training and financial support systems, are headquartered in Chesterfield, Missouri. During the year ended December 31. 2012, tube manufacturing and processing facilities for North America were maintained in eight locations, geographically dispersed throughout the United States and Canada.

The Company also conducts Insituform CIPP process rehabilitation operations worldwide through its wholly owned subsidiaries and through direct and indirect joint venture relationships. The results from these operations are included in its European Water and Wastewater and Asia-Pacific Water and Wastewater operating segments, as appropriate. The Company utilize multifunctional robotic devices developed by its French subsidiary in connection with the inspection and repair of pipelines. The Company also maintain a manufacturing facility in Wellingborough, United Kingdom to support European operations and through wh! ich the C! ompany sell liners to third parties.

Commercial and Structural Operations

The Company�� commercial and structural operations perform rehabilitation and strengthening of pipelines, buildings, bridges, tunnels and waterfront structures throughout the United States and Canada through Fibrwrap Construction Services, headquartered in Ontario, California, in its Asian markets through Its wholly owned subsidiaries and through Its joint ventures in Borneo and Indonesia and in its Latin American markets through its joint ventures in Chile, Colombia, Costa Rica and Peru. Through Fyfe Co., headquartered in San Diego, California, the Company designs and manufactures the FRP composite systems used in these applications. It�� wholly owned Fyfe entities located in El Salvador, Singapore, Japan, Malaysia and Hong Kong and its Fyfe joint ventures in Borneo and Indonesia, provide product and engineering services throughout Latin America and Asia-Pacific. Its licensee in Greece provides product and services throughout the Middle East and Europe.

Advisors' Opinion:

• [By Alexis Xydias]

  The ISEQ Index (ISEQ) in Ireland and the ASE Index in Greece, the first two nations to receive European Union-led bailouts, have soared more than 28 percent this year to lead gains among 18 national benchmarks in western Europe. Dublin-based Independent News & Media Plc (INM) and Athens-based Aegean Airlines SA (AEGN) rose the most, with jumps of more than 180 percent. Germany�� DAX Index (DAX) has advanced 18 percent in 2013, reaching a record.

• [By CRWE]

  Aegion Corporation (Nasdaq:AEGN) reported the award today of two subcontracts for its Malaysian subsidiary, Insituform Linings Asia Sdn Bhd, with a total value of approximately $9.3 million (USD).

• [By Damian Illia]

  Finally, I always like to see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the return on equity. The ratio has decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness. Moreover, it is worse than those shown in the table like Aegion Corporation (AEGN), EnerNOC Inc. (ENOC), MYR GroupInc. (MYRG) and Pike Corporation (PIKE).

Top 5 Clean Energy Companies To Buy For 2014: Peregrine Pharmaceuticals Inc.(PPHM)

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections. Its products under development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metasta tic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., provides integrated current Good Manufacturing Practices (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has licensing agreements with the University of Texas Southwestern Medical Center; Merck KGaA; SuperGen, Inc.; and Affitech A/S. Peregrine Pharmaceuticals, Inc. intends to sell its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.

Advisors' Opinion:

• [By Rick Munarriz]

  Peregrine Pharmaceuticals (NASDAQ: PPHM  ) is an upstart biotech targeting the treatment and diagnosis of cancer through monoclonal antibodies. It has a potential winner in its lead candidate that will begin its telltale phase 3 clinical trial later this year.

• [By Sean Williams]

  What: Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM  ) , a biopharmaceutical company developing monoclonal antibodies to treat cancer, jumped as much as 19% after the company reported final data on its mid-stage second-line non-small cell lung cancer drug, Bavituximab, at the annual American Society of Clinical Oncology meeting.

Top 5 Clean Energy Companies To Buy For 2014: TESARO Inc (TSRO)

TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.

Rolapitant

Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.

TSR-011

TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.

The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading UP
  Tesaro (NASDAQ: TSRO) shares shot up 18.28 percent to $28.40 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant.

• [By Keith Speights]

  Positive response
  Clovis wasn't the only company to bring good news about an ovarian cancer drug to ASCO. TESARO� (NASDAQ: TSRO  ) announced phase 1 results for�niraparib. Shares of the biotech jumped 16% for the week.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Tesaro (NASDAQ: TSRO) shares shot up 20.78 percent to $29.00 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant.

Top 5 Clean Energy Companies To Buy For 2014: Stewart Enterprises Inc.(STEI)

Stewart Enterprises, Inc., through its subsidiaries, provides funeral and cemetery products and services in the death care industry in the United States and Puerto Rico. The company also offers a range of funeral merchandise and services, as well as cemetery property, cremation, merchandise, and services. Its funeral homes provide various services and products, including the family consultation, removal and preparation of remains, usage of funeral home facilities for visitation, worship and funeral services, transportation services, flowers, and caskets. The company also sells cemetery property and related merchandise, which includes lots, lawn crypts, family and community mausoleums, monuments, markers, and burial vaults; and provides burial site openings and closings and inscriptions. In addition, it maintains cemetery grounds under cemetery perpetual care contracts and local laws. As of January 31, 2011, the company owned and operated 218 funeral homes and 141 cemeterie s. Stewart Enterprises, Inc. was founded in 1910 and is based in Jefferson, Louisiana.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of funeral-home operator Stewart Enterprises (NASDAQ: STEI  ) soared 34% today, after larger rival Service Corp. International (NYSE: SCI  ) agreed to acquire it in a deal worth about $1.4 billion.

• [By Chris Katje]

  Service Corporation (SCI), the largest funeral home operator in the United States, made news last week with its large acquisition of Stewart Enterprises (STEI). The acquisition was well received by investors, as shares rose 8% on the day of the announcement. Together, the two companies will see huge cost savings advantages and a backlog that is currently undervalued.